English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessMoneycontrol ResearchSun Pharma: Fully valued, though performance impressive

    Sun Pharma: Fully valued, though performance impressive

    Sales of specialty products during the reporting quarter clocked $157 million against $148 million in Q1FY22 and $108 million in Q2FY21.

    Anubhav Sahu
    November 03, 2021 / 10:35 IST
    Sun Pharma: Fully valued, though performance impressive

    • PRO Panorama

      Moneycontrol Pro Panorama | Will US Fed rate cuts reverse slowdown in Indian IT?

      Sep 9, 2025 / 03:30 PM IST

      In September 9 edition of Moneycontrol Pro Panorama: Understanding the politics behind the social media ban in Nepal, decoding the...

      Read Now
    • PRO Weekender

      Moneycontrol Pro Weekender | GST in Gloriously Silly Terms

      Sep 6, 2025 / 10:00 AM IST

      GST saw a Glorious Structural Turnaround this week and many other acronyms

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts

    Disclosure & Disclaimer

    This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More